<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN">
<html>
  <head>
    <meta http-equiv="content-type" content="text/html; charset=UTF-8">
    <title>Ebola patents</title>
  </head>
  <body>
    <blockquote><br>
      <img alt="" src="0logo.gif" height="82" width="124"><br>
      <a href="../index.htm"><b>rexresearch.com</b></a><b><br>
      </b>
      <hr size="2" width="100%"><b><br>
      </b>
      <div align="center"><big><big><b>Ebola ( Filovirus ) &amp; Related
              Diseases ( Marburg Virus, Lassa Fever, Hemorrhagic Fever,
              &amp;c ) : </b></big></big><br>
        <big><big><b>Patents &amp; Applications</b></big></big><br>
      </div>
      <b><br>
      </b>
      <hr size="2" width="100%">
      <div align="center"><br>
        <script type="text/javascript"><!--
google_ad_client = "pub-2924514667432343";
google_ad_width = 728;
google_ad_height = 90;
google_ad_format = "728x90_as";
google_ad_type = "text_image";
//2007-01-05: http://www.rexresearch.com
google_ad_channel = "5682237150";
//--></script><br>
        <script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
</script>
        <script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
</script>
        <script type="text/javascript"><!--
google_ad_client = "pub-2924514667432343";
google_ad_width = 728;
google_ad_height = 90;
google_ad_format = "728x90_as";
google_ad_type = "text_image";
//2007-01-05: http://www.rexresearch.com
google_ad_channel = "5682237150";
//--></script>
        <script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
</script>
        <script type="text/javascript"><!--
google_ad_client = "pub-2924514667432343";
google_ad_width = 728;
google_ad_height = 90;
google_ad_format = "728x90_as";
google_ad_type = "text_image";
//2007-01-05: http://www.rexresearch.com
google_ad_channel = "5682237150";
//--></script><br>
        <br>
      </div>
      <hr size="2" width="100%"><b><br>
      </b><b>Got Ebola ? </b><b>( Got Tetrasilver Tetroxide ?</b><b> )</b><b><br>
      </b><b><br>
      </b>
      <div align="center"><b><img alt="" src="ebola.jpg" height="168"
            width="300"> </b><br>
      </div>
      <div align="center"><b>&nbsp;<img alt="" src="ebola2.jpg"
            height="535" width="354"><br>
          <br>
        </b>
        <hr size="2" width="100%"></div>
      <b><br>
      </b><a href="http://espacenet.com"><b>http://espacenet.com</b></a><b><br>
        <br>
      </b><b>COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A
        GENE FROM THE EBOLA</b><b><br>
      </b><b>US8735369</b><b><br>
      </b>&nbsp;<br>
      The invention relates to a double-stranded ribonucleic acid
      (dsRNA) for inhibiting the expression of a gene from the Ebola
      virus.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>INHIBITORS OF PROTEIN PHOSPHATASE-1 AND USES THEREOF</b><b><br>
      </b><b>WO2014028051 </b><b><br>
      </b><br>
      Inhibitors of protein phosphatase-1 (PP-1 ) and their use in a
      method for the treatment or prevention of viral infections caused
      by HIV or ebola virus are disclosed. Inhibitors of protein
      phosphatase-l in effective amounts have been shown to slow down
      viral replication upon contacting ebola virus or cells containing
      the ebola virus.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>EBOLA VIRUS LIPOSOME VACCINE</b><b><br>
      </b><b>WO2012050193</b><b><br>
      </b><br>
      The present invention provides a peptide-bonded liposome that is a
      liposome to which a peptide is bonded, the peptide being an ebola
      virus antigen peptide that can induce cytolytic T lymphocytes
      restricted to HLA-A*0201 or HLA-A*2402, the liposome containing a
      liposome stabilization agent and a phospholipid having a acyl
      group having 14-24 carbon atoms and one unsaturated bond or a
      hydrocarbon group having 14-24 carbon atoms and one unsaturated
      bond, and the peptide being bonded to the surface of the liposome.
      Also, the present invention provides an ebola virus antigen
      peptide that can induce cytolytic T lymphocytes restricted to
      HLA-A*0201 or HLA-A*2402. The peptide-bonded liposome and the
      peptide are useful as an ebola virus vaccine or a cytolytic T
      lymphocyte activation agent.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Filovirus fusion proteins and their uses</b><b><br>
      </b><b>US2013323243</b><b><br>
      </b><br>
      Also published as: CN103596587 // WO2012154203 //&nbsp;
      US2013323243<br>
      <br>
      This invention provides fusion proteins comprising a Filovirus
      glycoprotein segment and an immunoglobulin polypeptide segment.
      The fusion proteins are useful in immunogenic compositions to
      protect against infections by Filoviruses, such as Ebola virus, in
      both humans and non-human animals. The fusion proteins are also
      useful in diagnostic assays to detect Filovirus infections.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A
        FILOVIRUS INFECTION</b><b><br>
      </b><b>US8703735</b><b><br>
      </b><br>
      Also published as:&nbsp; US8198429 // US8524684 <br>
      <br>
      The present invention provides antisense antiviral compounds,
      compositions, and methods of their use and production, mainly for
      inhibiting the replication of viruses of the Filoviridae family,
      including Ebola and Marburg viruses. The compounds, compositions,
      and methods also relate to the treatment of viral infections in
      mammals including primates by Ebola and Marburg viruses. The
      antisense antiviral compounds include phosphorodiamidate
      morpholino oligonucleotides (PMOplus) having a nuclease resistant
      backbone, about 15-40 nucleotide bases, at least two but typically
      no more than half piperazine-containing intersubunit linkages, and
      a targeting sequence that is targeted against the AUG start site
      region of Ebola virus VP35, Ebola virus VP24, Marburg virus VP24,
      or Marburg virus NP, including combinations and mixtures thereof.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>BROAD SPECTRUM INHIBITORS OF THE POST PROLINE CLEAVING ENZYMES
        FOR TREATMENT OF HEPATITIS C VIRUS INFECTIONS</b><b><br>
      </b><b>WO2014022636 </b><b><br>
      </b><br>
      Disclosed are methods of treating, inhibiting, or preventing a
      viral infection in a mammal in need thereof by administering a
      therapeutically or prophylactically effective amount of an
      inhibitor of FAP, an inhibitor of DPPIV, an inhibitor of DPP8, or
      an inhibitor of DPP9. The inhibitor may act as both an inhibitor
      of DPPIV and an inhibitor of DPP8/9. The viral infection includes,
      but is not limited to, hepatitis B virus, hepatitis C virus, human
      immunodeficiency virus, Polio virus, Coxsackie A virus, Coxsackie
      B virus, Rhino virus, respiratory syncytial virus, dengue virus,
      equine infectious anemia virus, Echo virus, small pox virus, Ebola
      virus, and West Nile virus.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED
        DISEASES</b><b><br>
      </b><b>US8475804</b><b><br>
      </b><br>
      The invention features compositions, methods, and kits useful for
      the treatment of filovirus-mediated diseases, e.g., hemorrhagic
      fever caused by Ebola virus, in an animal.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSES</b><b><br>
      </b><b>WO2013154778 </b><b><br>
      </b><br>
      Novel antiviral compounds of Formulae (I)-(III) are provided: (I)
      (II) (III) The inventive compounds, pharmaceutical compositions
      thereof, and kits including the inventive compounds are useful for
      the prevention and treatment of infectious diseases caused by
      viruses, for example, by Flaviviridae virus (e.g., Dengue virus
      (DENY)), Kunjin virus, Japanese encephalitis virus, vesicular
      stomatitis virus (VSV), herpes simplex virus 1 (HSV-1), human
      cytomegalovirus (HCMV), poliovirus, Junin virus, Ebola virus,
      Marburg virus (MARV), Lassa fever virus (LASV), Venezuelan equine
      encephalitis virus (VEEV), or Rift Valley Fever virus (RVFV).<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS,
        PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING
        HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH
        ARENA VIRUSES</b><b><br>
      </b><b>US8664274 </b><b><br>
      </b><br>
      Also published as: WO2008147474 &nbsp;<br>
      <br>
      Compounds, methods and pharmaceutical compositions for treating
      viral infections, by administering certain novel sulfonyl
      semicarbazides, carbonyl semicarbazides, semicarbazides, ureas and
      related compounds in therapeutically effective amounts are
      disclosed. Methods for preparing the compounds and methods of
      using the compounds and pharmaceutical compositions thereof are
      also disclosed. In particular, the treatment and prophylaxis of
      viral infections such as caused by hemorrhagic fever viruses is
      disclosed, i.e., including but not limited to, Arenaviridae
      (Junin, Machupo, Guanarito, Sabia, Lassa, Tacaribe, Pinchinde, and
      VSV), Filoviridae (ebola and Marburg viruses), Flaviviridae
      (yellow fever, omsk hemorrhagic fever and Kyasanur Forest disease
      viruses), and Bunyaviridae (Rift Valley fever).<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>SMALL MOLECULE INHIBITORS OF EBOLA AND LASSA FEVER VIRUSES AND
        METHODS OF USE</b><b><br>
      </b><b>US2013231332 </b><b><br>
      </b><br>
      Also published as: WO2012031090<br>
      <br>
      The present invention relates to compositions and methods for the
      treatment of infection by enveloped viruses, such as Ebola and
      Lassa fever viruses.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>SET OF OLIGONUCLEOTIDE PRIMERS AND FLUORESCENT-MARKED PROBES
        FOR TYPE-SPECIFIC EXPRESS IDENTIFICATION OF EBOLA-ZAIRE VIRUS BY
        METHOD OF POLYMERASE CHAIN REACTION</b><b><br>
      </b><b>RU2487942 </b><b><br>
      </b><br>
      FIELD: biotechnologies.SUBSTANCE: invention relates to a set of
      oligonucleotide primers and fluorescent-marked probes for
      type-specific express-identification of the Ebola-Zaire virus by
      the method of polymerase chain reaction in real time. The set
      includes sequences that are type-specific for the Ebola-Zaire
      virus: external: 5'?' 5' CCACTTTTCTCAACCAAAATTATTAGTGA 3' 3'?5'
      5'TTCTCTAAATCAGTTACAAARCTACTCCC 3' internal: 5'?3'
      5'TGGGATCCAGTHTIYGARCC 3' 3'?5' 5' ACTACCATCATATTGCTAGGAAATGCTT 3'
      probe: FAM - TACTACCACAATATCGGAACTTTTCTTTCTCATTGAA - BHQ1.EFFECT:
      invention may be used in medicine for quick detection of genetic
      material of Ebola-Zaire virus.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>SET OF OLIGONUCLEOTIDE PRIMERS AND FLUORESCENT-LABELED PROBES
        FOR SPECIES-SPECIFIC EXPRESS-IDENTIFICATION OF VIRUS EBOLA-SUDAN
        BY METHOD OF POLYMERASE CHAIN REACTION</b><b><br>
      </b><b>RU2487167 </b><b><br>
      </b><br>
      FIELD: biotechnology.SUBSTANCE: invention relates to the field of
      biotechnology and is related to the set oligonucleotide primers
      and fluorescent-labeled probes for species-specific
      express-identification the virus Ebola-Sudan by the method of
      polymerase chain reaction in real time. The set comprises
      sequences species-specific for the virus Ebola-Sudan: external:
      5'?3' 5' CCGTTATTCTCYACRAAGRTSATTAGTGA 3' 3'?5' 5'
      TTCTCTAGGTCTGTGACAAAACTACTCCC 3' internal: 5'?3' 5'
      TGGGATGCAGTHTTYGARCC 3' 3'?5' 5' ACAACCATCATRTTGCTTGGAAAGGCTT 3'
      probe: FAM - TATTGCCCCAGAATCGAAATTTTTCTTTTTCATTGAA-BHQ1.EFFECT:
      invention can be used in medicine for rapid identification of the
      genetic material of the virus Ebola-Sudan.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Antiviral Drugs for Treatment of Arenavirus Infection</b><b><br>
      </b><b>US8492434</b><b><br>
      </b><br>
      Also published as: WO2007100888 // ZA200807506 <br>
      <br>
      Compounds, methods and pharmaceutical compositions for treating
      viral infections, by administering certain novel compounds in
      therapeutically effective amounts are disclosed. Methods for
      preparing the compounds and methods of using the compounds and
      pharmaceutical compositions thereof are also disclosed. In
      particular, the treatment and prophylaxis of viral infections such
      as caused by hemorrhagic fever viruses is disclosed, i.e.,
      including but not limited to, Arenaviridae (Junin, Machupo,
      Guanarito, Sabia, Lassa, Tacaribe, and Pichinde), Filoviridae
      (Ebola and Marburg viruses), Flaviviridae (yellow fever, Omsk
      hemorrhagic fever and Kyasanur Forest disease viruses), and
      Bunyaviridae (Rift Valley fever).<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>MAMMALIAN GENES AND GENE PRODUCTS INVOLVED IN INFECTION</b><b><br>
      </b><b>WO2013066442 </b><b><br>
      </b><b><br>
      </b>The present disclosure relates to mammalian genes and gene
      products that are involved in infection or are otherwise
      associated with the life cycle of one or more pathogens. Disclosed
      herein are methods of reducing infection of a cell by a pathogen,
      for example to treat or prevent a pathogen infection. Exemplary
      pathogens include HIV-1, HIV-2, influenza A, Marburg virus and
      Ebola virus. The disclosure also relates to methods of identifying
      agents involved in pathogen infection.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Fluorescent quantitative PCR (polymerase chain reaction)
        method, primer and kit for detecting EBOV (Ebola virus)</b><b><br>
      </b><b>CN103045755 </b><b><br>
      </b><br>
      The invention discloses a fluorescent quantitative PCR (polymerase
      chain reaction) method, primer and kit for detecting the EBOV
      (Ebola virus). The general method can be used for detecting that
      the sample to be detected is positive as long as the sample
      contains one or more of the five types of subtype EBOVs which are
      Z, S, B, C and R at the same time. The method overcomes the
      defects of the conventional PCR method for detecting by adopting
      the advantages of high-efficiency nucleic acid amplification of
      the PCR technology and the sensitivity of the fluorescence-dye
      SYBR Green I and the computer-aided fluorescent technology for
      detecting and improves the detection sensitivity, specificity and
      operation convenience greatly. In addition, the positive control
      adopted by the method is a section of RNA molecules transcribed in
      vitro of a NP gene, and the method is safer than the method for
      detecting by taking the inactivated virus solution as the positive
      control. The RNA molecules transcribed in vitro can be prepared in
      quantity, and the sources of the positive control are stable and
      reliable.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>One-step process real-time fluorescent quantitative RT-PCR
        (Reverse Transcription-Polymerase Chain Reaction) method and kit
        for detecting Z/S subtype ebola viruses</b><b><br>
      </b><b>CN103045754 </b><b><br>
      </b><br>
      The invention discloses a one-step process real-time fluorescent
      quantitative RT-PCR (Reverse Transcription-Polymerase Chain
      Reaction) method and kit as well as a primer and a probe for
      detecting Z/S subtype ebola viruses (EBOV). The one-step process
      real-time fluorescent quantitative RT-PCR method is a general
      detection method; and the PCR detection process can be used for
      detecting Z and S subtype EBOVs after being carried out once. A
      sample is positive as long as any one of the Z and S subtype EBOVs
      or both the Z and S subtype EBOVs exist in the sample to be
      detected. The one-step process MGB (Minor Groove Binder) probe
      fluorescent quantitative RT-PCR technology provided by the
      invention combines the advantages of efficient amplification of
      nucleic acids in a PCR technology and sensitivity of a MGB probe
      and a computer-assisted fluorescence detection technology,
      overcomes the shortcomings of conventional PCR detection and
      greatly increases detection sensitivity, specificity and
      convenience of operation.<br>
      <br>
      <hr size="2" width="100%"><b><br>
        Inhibition of TCR Signaling with Peptide Variants</b><b><br>
      </b><b>US2013039948 </b><b><br>
      </b><br>
      The present invention provides compositions comprising peptides
      derived from amino acid sequences (or from combinations thereof)
      of fusion and other protein regions of various viruses, including
      but not limited to, severe acute respiratory syndrome coronavirus,
      herpesvirus saimiri, human herpesvirus 6, Lassa virus, lymphocytic
      choriomeningitis virus, Mopeia virus, Tacaribe virus, Friend
      murine leukemia virus; human T lymphotropic virus type 1;
      herpesvirus ateles; Marburg virus; Sudan Ebola virus; Zaire Ebola
      virus, and comprising L- and/or D-amino acids and combinations
      thereof, which affect T cells by acting on the T cell antigen
      receptor (TCR). More specifically, the peptides act on the
      TCR[alpha][beta]-CD3[delta][epsilon]-CD3[gamma][epsilon]-[zeta][zeta]
      signaling complex. Yet more specifically, the peptides act on the
      TCR[alpha]/CD3[delta][epsilon]/[zeta][zeta] signaling module of
      TCR. The present invention further relates to the prevention and
      therapy of various T cell-related disease states involving the use
      of these compositions. Specifically, the compositions are useful
      in the treatment and/or prevention of a disease or condition where
      T cells are involved or recruited. The compositions of the present
      invention also are useful in the production of medical devices
      comprising peptide matrices (for example, medical implants and
      implantable devices).<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>SMALL MOLECULE INHIBITORS OF EBOLA AND LASSA FEVER VIRUSES</b><b><br>
      </b><b>WO2013022550 </b><b><br>
      </b><br>
      The present invention relates to compositions and methods for the
      treatment of infection by enveloped viruses, such as Ebola and
      Lassa fever viruses.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>HEPATITIS C THERAPY</b><b><br>
      </b><b>US8163703</b><b><br>
      </b><br>
      Also published as: WO2006104945 // JP2012229216<br>
      <br>
      PROBLEM TO BE SOLVED: To provide compounds which inhibit HCV viral
      polymerase. ; SOLUTION: The present invention relates to certain
      fused furan, thiophene and pyrrole compounds and particularly to
      fused furan, thiophene and pyrrole compounds that are useful as
      inhibitors of hepatitis B, hepatitis C, Polio, Coxsackie A and B,
      Rhino, Echo, small pox, Ebola, and West Nile virus polymerases.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Monoclonal Antibodies for Ebola and Marburg Viruses</b><b><br>
      </b><b>US8513391</b><b><br>
      </b><br>
      Described herein are a number of Ebola and Marburg monoclonal
      antibodies.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Lipid Formulated Compositions and Methods for Inhibiting
        Expression of a Gene from the Ebola Virus</b><b><br>
      </b><b>US2012270921 </b><b><br>
      </b><br>
      Also published as: WO2011020023 // EP2464336 <br>
      <br>
      The invention relates to lipid formulated double-stranded
      ribonucleic acid (dsRNA) for inhibiting the expression of a gene
      from the Ebola virus.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>THERAPEUTIC FUROPYRIMIDINE AND THIENOPYRIMIDINE</b><b><br>
      </b><b>US8133870</b><b><br>
      </b><b>JP2012167126 </b><b><br>
      </b><br>
      Also published as: WO2006050161 // JP2012167126 &nbsp;<br>
      <br>
      PROBLEM TO BE SOLVED: To provide therapeutic furopyrimidines and
      thienopyrimidines. ; SOLUTION: The invention provides compounds of
      formula I, II, and III as described herein, as well as
      pharmaceutical compositions comprising the compounds, and
      synthetic methods and intermediates that are useful for preparing
      the compounds. The compounds of formula I, II, and III are useful
      as anti-viral agents and/or as anti-cancer agents. The present
      invention provides compounds that are inhibitors of viral RNA and
      DNA polymerases (e.g. polymerases from hepatitis B, hepatitis C,
      human immunodeficiency virus, Polio, Coxsackie A and B, Rhino,
      Echo, small pox, Ebola, and West Nile virus) and that are useful
      for treating HCV, as well as other viral infections (e.g.
      flaviviral infections), and cancer.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Multiplex fluorescent polymerase chain reaction (PCR) kit and
        primers for detecting Ebola viruses, Marburg viruses, Lassa
        viruses and Rift Valley fever viruses</b><b><br>
      </b><b>CN102719557 </b><b><br>
      </b><br>
      The invention provides a multiplex fluorescent polymerase chain
      reaction (PCR) kit and primers for detecting Ebola viruses,
      Marburg viruses, Lassa viruses and Rift Valley fever viruses. The
      multiplex fluorescent PCR kit comprises conventional reagents of
      an RT-PCR buffer and an RT-PCR enzyme mixed liquor and also
      comprises primers and probes for detecting the four viruses,
      wherein the primers are shown in sequences of SEG ID NO: 1-13 and
      the probes are shown in sequences of SEQ ID NO: 14-18. The
      multiplex fluorescent PCR kit, the primers and the probes realize
      rapid and accurate detection of pathogens of Ebola hemorrhagic
      fever, Marburg hemorrhagic fever, Lassa fever and Rift Valley
      fever, prevent the four infectious diseases from spreading into or
      out of the frontier port, are accurate and effective, have strong
      operability, and can be used for detection of the infectious
      diseases.; Through the multiplex fluorescent PCR kit, the primers
      and the probes, suspect cases can be found timely and a capability
      of preventing the infectious diseases from spreading into our
      country is improved.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Human Ebola Virus Species and Compositions and Methods Thereof</b><b><br>
      </b><b>US2012251502 </b><b><br>
      </b><br>
      Also published as: WO2010048615 // EP2350270 // CA2741523<br>
      <br>
      Compositions and methods including and related to the Ebola
      Bundibugyo virus (EboBun) are provided. Compositions are provided
      that are operable as immunogens to elicit and immune response or
      protection from EboBun challenge in a subject such as a primate.
      Inventive methods are directed to detection and treatment of
      EboBun infection.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Antiviral therapeutic agents comprising fused tricyclic
        compounds comprising a pyrrolo[1.2-f][1,2,4]triazine moiety</b><b><br>
      </b><b>US7994139</b><b><br>
      </b><br>
      Also published as: WO2009111653<br>
      <br>
      Disclosed are pyrrolo[2,1-f][1,2,4]triazine compounds of formula I
      wherein ring B is a 5, 6, 7 or 8 membered heterocyclic ring
      comprising one or more double bonds, and is substituted with one
      or more oxo, thioxo or SO2R' group, salts thereof and methods for
      the compounds' preparation. The compounds of formula I are useful
      for treating cancer and viral infections such as hepatitis B,
      hepatitis C (HCV), human immunodeficiency virus (HIV), Polio,
      Coxsackie A and B, Rhino, Echo, small pox, Ebola, and West Nile
      virus.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>GENERATION OF VIRUS-LIKE PARTICLES AND USE AS PANFILOVIRUS
        VACCINE</b><b><br>
      </b><b>CA2768801 </b><b><br>
      </b><br>
      In this application are described filovirus-like particles for
      both Ebola and Marburg and their use as a diagnostic and
      therpeutic agent as well as a filovirus vaccine. Also described is
      the association of Ebola and Marburs with lipid rafts during
      assembly and budding, and the requirement of functional rafts for
      entry of filoviruses into cells.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>INHIBITORS OF FILOVIRUS ENTRY INTO HOST CELLS</b><b><br>
      </b><b>US2012189614 </b><b><br>
      </b><br>
      Also published as: WO2011046646 // EP2451278 // CA2767541 //
      AU2010307262<br>
      <br>
      Organic compounds showing the ability to inhibit viral
      glycoprotein (GP)-mediated entry of a filovirus into a host cell
      are disclosed. The disclosed filovirus entry inhibitor compounds
      are useful for treating, preventing, or reducing the spread of
      infections by filovirus including the type species Marburg virus
      (MARV) and Ebola virus (EBOV). Preferred inhibitors of the
      invention provide therapeutic agents for combating the Ivory
      Coast, Sudan, Zaire, Bundibugyo, and Reston Ebola virus strains.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Anti-TSG101antibodies and their uses for treatment of viral
        infections</b><b><br>
      </b><b>US7964708</b><b><br>
      </b><br>
      Also published as: WO2008064072 // EP2514439<br>
      <br>
      The present invention provides antibodies that bind to the
      C-terminal region of TSG101. The invention also provides these
      antibodies for use in the treatment of viral infections, including
      HIV and Ebola virus infection.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>MONOCLONAL ANTIBODIES AGAINST GLYCOPROTEIN OF EBOLA SUDAN
        BONIFACE VIRUS</b><b><br>
      </b><b>US2012164153 </b><b><br>
      </b><br>
      Also published as: WO2011071574 //EP2473525<br>
      <br>
      We disclose Ebola Sudan Boniface virus GP Monoclonal antibodies,
      epitopes recognized by these monoclonal antibodies, and the
      sequences of the variable regions of some of these antibodies.
      Also provided are mixtures of antibodies of the present invention,
      as well as methods of using individual antibodies or mixtures
      thereof for the detection, prevention, and/or therapeutic
      treatment of Ebola Sudan Boniface virus infections in vitro and in
      vivo.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>EARLY DIAGNOSTIC TECHNIQUE FOR EBOLA HEMORRHAGIC FEVER IN
        INDIVIDUALS PRESUMABLY INFECTED WITH SUCH VIRUS</b><b><br>
      </b><b>RU2450274 </b><b><br>
      </b><br>
      FIELD: medicine. ^ SUBSTANCE: blood serum is sampled from
      individuals presumably infected with such virus for the first time
      in 3-4 hours and for the second time - in 15-18 hours after
      presumed infection. Each serum sample is examined for a level of
      hemolytic complement activity (HCA) by any known technique. If
      observing the HCA in 1.5-2.0 times and more for a specified period
      of time, the fact of body infection is stated, and the absence or
      minor change of the HCA shows the absence of body infection. The
      HCA level can be evaluated by unified technique showing intact
      sheep erythrocyte lysis with commercial hemolytic anti-sheep
      rabbit serum. ^ EFFECT: use of the technique enables earlier
      diagnosing of Ebola hemorrhagic fever that will allow prescribing
      a complete complex of therapeutic actions immediately<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>OPTIMIZED VACCINES TO PROVIDE PROTECTION AGAINST EBOLA AND
        OTHER VIRUSES</b><b><br>
      </b><b>US8101739</b><b><br>
      </b><br>
      Also published as: WO2006037038<br>
      <br>
      The invention is related to a nucleic acid molecule comprising a
      polynucleotide encoding a modified filovirus glycoprotein (GP)
      having at least one amino acid change located in a relatively
      conserved region of said GP that decreases in vitro cytotoxicity
      and retains immunogenicity when compared to in vitro cytotoxicity
      and immunogenicity of a wild type filovirus GP, and related
      modified filovirus GPs, plasmid DNAs, recombinant viruses,
      adenoviruses, pharmaceutical compositions, vaccine compositions,
      antibodies that are specifically reactive with the modified
      filovirus GPs, and related methods of making and using the same.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>ANTIVIRAL NUCLEOSIDE ANALOGS</b><b><br>
      </b><b>US8440813</b><b><br>
      </b><br>
      Also published as: WO2008089105 // SI2114980 // NZ578556 <br>
      <br>
      Disclosed is the use of a compound of formula (I) in the
      manufacture of a medicament for treating viral infections where in
      the substituents are as disclosed in the specification and
      examples of compounds of formula (I) are:
      (2S,3R,4R,5R)-2-(4-Aminopyrrolo[1,2-j][1,2,4]triazin-7-yl)-5-(hydroxymethyl)-3-methyltetrahydrofuran-3,4-diol;









      (2S,3R,4R,5R)-2-(4-(Dimethylamino)pyrrolo[1,2-j][1,2,4]triazin-7-yl)-5-(hydroxymethyl)-3-methyltetrahydrofuran-3,4-diol;









      and
      (2S,3R,4R,5R)-2-(4-Amino-5-bromopyrrolo[1,2-j][1,2,4]triazin-7-yl)-5-(hydroxymethyl)-3-methyltetrahydrofuran-3,4-diol.









      Examples of the viral infection are from the group consisting of:
      hepatitis B, hepatitis C, human immunodeficiency virus, Polio,
      Coxsackie A and B, Rhino, Echo, small pox, Ebola, and West Nile
      virus.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS,
        PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING
        HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH
        ARENAVIRUSES</b><b><br>
      </b><b>WO2012060820 </b><b><br>
      </b><br>
      Compounds, methods and pharmaceutical compositions for treating
      viral infections, by administering certain novel semicarbazides,
      sulfonyl carbazides, ureas and related compounds in
      therapeutically effective amounts are disclosed. Methods for
      preparing the compounds and methods of using the compounds and
      pharmaceutical compositions thereof are also disclosed. In
      particular, the treatment and prophylaxis of viral infections such
      as caused by hemorrhagic fever viruses is disclosed, i.e.,
      including but not limited to Arenaviridae (Junin, Machupo,
      Guanavito, Sabia and Lassa), Filoviridae (ebola and Marburg
      viruses), Flaviviridae (yellow fever, omsk hemorrhagic fever and
      Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley
      fever).<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Recombinant proteins from filoviruses and their use</b><b><br>
      </b><b>US7947286</b><b><br>
      </b><br>
      Also published as: WO2007044731<br>
      <br>
      Filovirus subunit protein immunogens are produced using a
      recombinant expression system and combined with one or more
      adjuvants in immunogenic formulations. The subunit proteins
      include GP95, GP-FL, VP40, VP24, and NP derived from Ebola Virus
      and Marburg Virus. Adjuvants include saponins, emulsions, alum,
      and dipeptidyl peptidase inhibitors. The disclosed immunogenic
      formulations are effective in inducing strong antibody responses
      directed against individual Filovirus proteins and intact
      Filovirus particles as well as stimulating cell-mediated immune
      responses to the Filoviruses.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>C-ABL TYROSINE KINASE INHIBITORS USEFUL FOR INHIBITING
        FILOVIRUS REPLICATION</b><b><br>
      </b><b>WO2012118599 </b><b><br>
      </b><br>
      This disclosure provides method of treating a Filoviridae viral
      infection, such as an Ebola virus infection or a Marburg virus
      infection, comprising providing an effective amount of a c-Abl
      tyrosine kinase inhibitor to a patient in need thereof. The c-Abl
      tyrosine kinase inhibitor may be a biological inhibitor that
      decreases expression of the c-Abl tyrosine kinase, such as a c-Abl
      tyrosine kinase specific siRNA. However it is preferred that the
      c-Abl tyrosine kinase inhibitor is a small molecule c-Abl tyrosine
      kinase antagonist. Suitable c-Abl tyrosine kinase antagonists
      include dasatinib, imatinib, and nilotinib and the
      pharmaceutically acceptable salts thereof<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS,
        PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING
        HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH
        ARENAVIRUSES</b><b><br>
      </b><b>US8410149</b><b><br>
      </b><b><br>
      </b>Compounds, methods and pharmaceutical compositions for
      treating viral infections, by administering certain novel
      semicarbazides, sulfonyl carbazides, ureas and related compounds
      in therapeutically effective amounts are disclosed. Methods for
      preparing the compounds and methods of using the compounds and
      pharmaceutical compositions thereof are also disclosed. In
      particular, the treatment and prophylaxis of viral infections such
      as caused by hemorrhagic fever viruses is disclosed, i.e.,
      including but not limited to Arenaviridae (Junin, Machupo,
      Guanavito, Sabia and Lassa), Filoviridae (ebola and Marburg
      viruses), Flaviviridae (yellow fever, omsk hemorrhagic fever and
      Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley
      fever).<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Generation of virus-like particles and use as panfilovirus
        vaccine</b><b><br>
      </b><b>US2011280904 </b><b><br>
      </b><br>
      In this application are described filovirus-like particles for
      both Ebola and Marburg and their use as a diagnostic and
      therapeutic agent as well as a filovirus vaccine. Also described
      is the association of Ebola and Marburg with lipid rafts during
      assembly and budding, and the requirement of functional rafts for
      entry of filoviruses into cells.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>COMPOSITIONS AND METHODS FOR TREATING EBOLA VIRUS INFECTION</b><b><br>
      </b><b>US2011217328 </b><b><br>
      </b><br>
      Also published as: WO2009116983<br>
      <br>
      The compositions and methods of the invention described herein
      provide treatments against Ebola virus infection by expressing
      gene(s) from the Ivory Coast ebolavirus (ICEBOV) species in a
      recombinant viral vector.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Marburg and Ebola dual-virus fluorescent quantitative PCR
        (Polymerase Chain Reaction) detection method and system</b><b><br>
      </b><b>CN102140533 </b><b><br>
      </b><br>
      The invention discloses Marburg and Ebola dual-virus fluorescent
      quantitative PCR (Polymerase Chain Reaction) detection method and
      system, wherein the detection system comprises primers, probes, a
      Premix EX Taq reaction solution and sterilizing Tris water. As two
      pairs of primers and probes have very good specificity, the
      detection system has high sensitivity and is suitable for
      simultaneously detecting Marburg and Ebola viruses without having
      cross reaction with other kinds of hemorrhagic fever arbovirus,
      such as yellow fever, dengue and rift valley fever.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Novel Ebola virus fluorescent quantitative PCR (Polymerase
        Chain Reaction) detection method and system</b><b><br>
      </b><b>CN102140532 </b><b><br>
      </b><br>
      The invention discloses Novel Ebola virus fluorescent quantitative
      PCR (Polymerase Chain Reaction) detection method and system,
      wherein the detection system comprises a primer, a probe, a Premix
      EX Taq reaction solution and sterilizing Tris water. As the primer
      and the probe has good detection specificity, the detection system
      has high sensitivity and is suitable for detecting Ebola viruses
      without having cross reaction with Marburg viruses.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Novel Marburg virus fluorescent quantitative PCR (Polymerase
        Chain Reaction) detection method and Marburg virus PCR detection
        system</b><b><br>
      </b><b>CN102140531 </b><b><br>
      </b><br>
      The invention discloses a novel Marburg virus fluorescent
      quantitative PCR (Polymerase Chain Reaction) detection method and
      a Marburg virus PCR detection system. The system consists of a
      primer, a probe, Premix Ex Tag reaction liquid and sterilized Tris
      water. The primer and the probe have high detection specificity
      and high sensitivity, are very suitable for the Marburg virus, and
      do not undergoany cross reaction with an Ebola virus.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS GENE
        EXPRESSION</b><b><br>
      </b><b>US8716464</b><b><br>
      </b><br>
      Also published as: WO2011011447 <br>
      <br>
      The present invention provides compositions comprising therapeutic
      nucleic acids (e.g., interfering RNA such as siRNA) that target
      Ebola virus (EBOV) gene expression and methods of using such
      compositions to silence EBOV gene expression. More particularly,
      the invention provides unmodified and chemically modified
      interfering RNA which silence EBOV gene expression and methods of
      use thereof, e.g., for preventing or treating EBOV infections
      caused by one or more EBOV species such as Zaire EBOV. The
      invention also provides serum-stable nucleic acid-lipid particles
      comprising one or more interfering RNA molecules, a cationic
      lipid, and a non-cationic lipid, which can further comprise a
      conjugated lipid that inhibits aggregation of particles. Methods
      of silencing EBOV gene expression by administering one or more
      interfering RNA molecules to a mammalian subject are also
      provided.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>CELL LINES AND HOST NUCLEIC ACID SEQUENCES RELATED TO
        INFECTIOUS DISEASE</b><b><br>
      </b><b>US7927793</b><b><br>
      </b><br>
      Also published as: WO2004070002 // EP1613724<br>
      <br>
      Host nucleic acids and host proteins that participate in viral
      infection, such as human immunodeficiency virus (HIV), influenza
      A, and Ebola virus, have been identified. Interfering with or
      disrupting the interaction between a host nucleic acid or host
      protein and a virus or viral protein confers an inhibition of or
      resistance to infection. Thus, interfering with such an
      interaction in a host subject can confer a therapeutic or
      prophylactic effect against a virus. The sequences identified can
      be used to identify agents that reduce or inhibit viral infection.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Anti-Viral Drugs for Treatment of Arenavirus Infection</b><b><br>
      </b><b>US8629170</b><b><br>
      </b><br>
      Also published as: WO2007103111<br>
      <br>
      Compounds, methods and pharmaceutical compositions for treating
      viral infections, by administering certain novel compounds in
      therapeutically effective amounts are disclosed. Methods for
      preparing the compounds and methods of using the compounds and
      pharmaceutical compositions thereof are also disclosed. In
      particular, the treatment and prophylaxis of viral infections such
      as caused by hemorrhagic fever viruses is disclosed, i.e.,
      including but not limited to, Arenaviridae (Junin, Machupo,
      Guanarito, Sabia, Lassa, Tacaribe, Pichinde, and LCMV),
      Filoviridae (Ebola and Marburg viruses), Flaviviridae (yellow
      fever, Omsk hemorrhagic fever and Kyasanur Forest disease
      viruses), and Bunyaviridae (Rift Valley fever).<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>NANOSTRUCTURED DEVICES INCLUDING ANALYTE DETECTORS, AND RELATED
        METHODS</b><b><br>
      </b><b>US2011171629 </b><b><br>
      </b><b><br>
      </b>Also published as: WO2011056936<br>
      <br>
      The present invention provides compositions and devices comprising
      nanostructure networks, and related methods. The compositions may
      exhibit enhanced interaction between nanostructures, providing
      improved device performance (e.g., improved conductivity). In some
      embodiments, the devices are capable of interacting with various
      species to produce an observable signal from the device. In some
      cases, the compositions and devices may be useful in the
      determination of analytes, including-biological analytes (e.g.,
      DNA, ebola virus, other infective agents, etc.), small, organic
      analytes, and the like. The embodiments described herein may
      exhibit high sensitivity and specificity to analytes and may be
      capable of analyte detection at femtomolar concentrations (e.g.,
      10 fM).<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>METHODS OF USE OF ANTIVIRAL COMPOUNDS</b><b><br>
      </b><b>US8440720</b><b><br>
      </b><br>
      The present invention relates, in part, to methods of treatment,
      prevention, and inhibition of viral disorders. In one aspect, the
      present invention relates to inhibition of the M2 proton channel
      of influenza viruses (e.g. influenza A virus) and other similar
      viroporins (e.g., VP24 of Ebola and Marburg viruses; and NS3
      protein of Bluetongue). The present invention further relates,
      inter alia, to compounds which have been shown to possess
      antiviral activity, in particular, inhibiting the M2 proton
      channel of influenza viruses.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Cobalt Hexammine as a Potential Therapeutic Against HIV and/or
        Ebola Virus</b><b><br>
      </b><b>US2011027388 </b><b><br>
      </b><br>
      Hexaamminecobalt(III) chloride, also called Cohex, reduces the
      extent of viral infection, including difficult to treat infections
      caused by Ebola virus and HIV. Disclosed are methods for treating
      a viral infection, comprising administering to a patient a
      cobalt(III) hexammine compound in an amount effective to reduce an
      extent of a viral infection. Also disclosed are kits for delivery
      of a cobalt(III) hexammine compound by injection.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>METHODS FOR PREVENTION AND TREATMENT OF INFECTIONS WITH
        SUPRAPHYSIOLOGICAL DOSES OF MANNAN-BINDING LECTIN (MBL) AND
        FICOLIN-MBL FUSION PROTEINS</b><b><br>
      </b><b>US2010331240 </b><b><br>
      </b><br>
      Also published as: WO2009126346<br>
      <br>
      The present invention provides methods of treatment and/or
      prevention of infections, for example, viral and bacterial
      infections, in individuals, wherein the method comprises
      administering a supraphysiological amount of mannose-binding
      lectin (MLB) and/or ficolin-MBL fusion protein to an individual
      afflicted with an infection or at risk of an infection, such as a
      bacterial or a viral infection. For example, methods for treatment
      and/or prevention of Ebola virus infection are provided.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION</b><b><br>
      </b><b>US7977365</b><b><br>
      </b><br>
      Also published as: CA2723086// WO2010036399 // JP2011518887<br>
      <br>
      Compounds, methods and pharmaceutical compositions for treating
      viral infections, by administering certain novel compounds in
      therapeutically effective amounts are disclosed. Methods for
      preparing the compounds and methods of using the compounds and
      pharmaceutical compositions thereof are also disclosed. In
      particular, the treatment and prophylaxis of viral infections such
      as caused by hemorrhagic fever viruses is disclosed, i.e.,
      including but not limited to, Arenaviridae (Junin, Machupo,
      Guanarito, Sabia, Lassa, Tacaribe, Pichinde, and LCMV),
      Filoviridae (Ebola and Marburg viruses), Flaviviridae (yellow
      fever, Omsk hemorrhagic fever and Kyasanur Forest disease
      viruses), and Bunyaviridae (Rift Valley fever and Crimean-Congo
      hemorrhagic fever).<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>STRAIN OF HYBRID ANIMAL CELLS Mus musculus L - PRODUCER OF
        MONOCLONAL ANTIBODIES FOR EXPOSING VP40 PROTEIN OF EBOLA VIRUS</b><b><br>
      </b><b>RU2395577 </b><b><br>
      </b><br>
      FIELD: chemistry; biochemistry. ^ SUBSTANCE: invention discloses a
      strain of hybrid animal cells Mus musculus L.4 A2, which is
      deposited in the Collection of cell cultures of the State Research
      Center of Virology and Biotechnology VECTOR, which is a producer
      of monoclonal antibodies which are specific to the matrix protein
      VP40 of the Ebola virus, Zaire subtype (Mainga strain), and a
      strain of hybrid animal cells Mus musculus L. 1C1 which is
      deposited in the Collection of cell cultures of the State Research
      Center of Virology and Biotechnology VECTOR, which is a producer
      of monoclonal antibodies which are specific to the matrix protein
      VP40 of the Ebola virus, Zaire subtype (Mainga strain). The
      invention is also aimed at obtaining monoclonal antibodies 4A2
      which are produced by the 4A2 hybridome, (subclass of
      immunoglobulins IgGl which have a heavy 55 kDa and a light 25 kDa
      chain) and are used as binding antigens in the "sandwich" format
      immunoenzymometric system for exposing the matrix protein VP40 of
      the Ebola virus, Zaire subtype (Mainga strain), and monoclonal
      antibodies 1C1 produced by the 1C1 hybridome (subclass of
      immunoglobulins IgGl which have a heavy 55 kDa and a light 25 kDa
      chain), used as biotin labelled indicators in the "sandwich"
      format immunoenzymometric system for exposing the matrix protein
      VP40 of the Ebola virus, Zaire subtype (Mainga strain). The
      disclosed antibodies are used together in a "sandwich" format
      immunoenzymometric system for exposing the matrix protein VP40 of
      the Ebola virus, Zaire subtype (Mainga strain). ^ EFFECT:
      invention enables to obtain monoclonal antibodies which are
      specific and do not compete with each other for antigen epitopes
      and which, when used together in a "sandwich" format
      immunoenzymometric system, ensure high reliability of results for
      exposing the matrix protein VP40 of the Ebola virus. <br>
      <br>
      <hr size="2" width="100%"><br>
      <b>STRAIN OF HYBRID ANIMAL CELLS Mus museums L - PRODUCER OF
        MONOCLONAL ANTIBODIES FOR EXPOSING NUCLEOPROTEIN OF EBOLA VIRUS</b><b><br>
      </b><b>RU2395576 </b><b><br>
      </b><br>
      FIELD: chemistry; biochemistry. ^ SUBSTANCE: invention discloses a
      strain of hybrid animal cells Mus musculus L. 1B2, which is
      deposited in the Collection of cell cultures of the State Research
      Center of Virology and Biotechnology VECTOR, which is a producer
      of monoclonal antibodies which are specific to the nucleoprotein
      of the Ebola virus, Zaire subtype (Mainga strain) and are used as
      binding antigens in a "sandwich" format immunoenzymometric system
      for exposing the neucleoprotein of the Ebola virus, Zaire subtype
      (Mainga strain), and a strain of hybrid animal cells Rattus
      Norvegicus 7B11 which is deposited in the Collection of cell
      cultures of the State Research Center of Virology and
      Biotechnology VECTOR and which is a producer of monoclonal
      antibodies which are specific to the nucleoprotein of Ebola virus,
      Zaire subtype (Mainga strain); and are used as biotin labelled
      indicators in the "sandwich" format immunoenzymometric system for
      exposing nucleoprotein of the Ebola virus, Zaire subtype (Mainga
      strain). The invention describes monoclonal antibodies 1B2 which
      are produced by the strain of hybrid animal cells Mus musculus L.
      1B2, which relate to the subclass of immunoglobulins IgGl which
      have a heavy 55 kDa and a light 25 kDa chain, and monoclonal
      antibodies 7B11 which are produced by the strain of hybrid animal
      cells Rattus Norvegicus 7B 11 related to the subclass of
      immunoglobulins IgG. The antibodies are used together in the
      "sandwich" format immunoenzymometric system for exposing
      nucleoprotein of the Ebola virus, Zaire subtype (Mainga strain). ^
      EFFECT: use of the invention enables to obtain results during "Ã„ "
      laboratory reseach and when designing a test system for highly
      reliable exposure of an antigen<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>INHIBITORS OF MICROBIAL INFECTIONS</b><b><br>
      </b><b>WO2011000721 </b><b><br>
      </b><br>
      The present invention finds application in the field of medicine
      and, in particular, it relates to new compounds for the treatment
      and/or prevention of HIV; Ebola, Dengue, Hepatitis C, SARS or
      tuberculosis infections.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Generation of virus-like particles and use as panfilovirus
        vaccines</b><b><br>
      </b><b>US2010143409 </b><b><br>
      </b><br>
      In this application are described filovirus-like particles for
      both Ebola and Marburg and their use as a diagnostic and
      therapeutic agent as well as a filovirus vaccine. Also described
      is the association of Ebola and Marburg with lipid rafts during
      assembly and budding, and the requirement of functional rafts for
      entry of filoviruses into cells.<br>
      <br>
      <hr size="2" width="100%"><b><br>
        AZOLE NUCLEOSIDES AND USE AS INHIBITORS OF RNA AND DNA VIRAL
        POLYMERASES</b><b><br>
      </b><b>US2010129317 </b><b><br>
      </b><br>
      Also published as: WO2008067002 // MX2009002707 // KR20090094800<br>
      <br>
      Azole nucleosides represented by the formulae (I) and (II);
      wherein A=C or N B-C or N X-H; C1-C6 alkyl, cycloalkyl, alkenyl,
      cycloalkenyl, alkynyl, aryl, heterocyclo, halogen such as F, Cl,
      Br and I; OH, NH2, NH-(C1-C6 alkyl, cycloalkyl, aryl or
      heterocyclo); Z-H; C1-C6 alkyl, cycloalkyl, alkynyl, aryl,
      heterocyclo, halogen such as F, Cl, Br, I; OH NH2, NH-(C1-C6
      alkyl, cycloalkyl, aryl or heterocyclo; E=(CH2)HONHR; n is an
      interger from 0-6 and more typically 0-3; R1= aryl or heterocyclo;
      each of W, Y, R is individually selected from the group consisting
      of H; C1-C6 alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl,
      aryl, heterocyclo, halogen such as F, Cl, Br, and I; O, OH,
      Oalkyl, Oaryl, NH2, NH(C1-C6 alkyl, cycloalkyl, aryl or
      heterocyclo); provided that at least one of W, Y, and R is other
      than H and wherein both W and Y together can be -O; and each D
      individually is OH, Oalkyl, Oaryl, FL and H; pharmaceutically
      acceptable salts thereof, prodrugs thereof and mixtures thereof
      are provided. Compounds of this disclosure are useful as
      inhibitors of viral RNA and DNA polymerases such as, but not
      limited to, Influenza, hantaan Virus, Crimean Congo hemorrhagic
      fever virus, hepatitis B, hepatitis C, Polio, Coxsackie A and B,
      Rhino, Echo, orthopoxvirus (small pox), HIV, Ebola, and West Nile
      virus polymerases; and especially orthopoxvirus, HIV, and
      hepatitis B.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>ODCASE INHIBITORS AS ANTI-VIRALS AND ANTIBIOTICS</b><b><br>
      </b><b>US8067391</b><b><br>
      </b><br>
      Also published as: WO2007038859 // ES2436404 // EP1931691<br>
      <br>
      The present invention includes the utility of anti-viral and/or
      antibacterial effective amounts of 6-substituted nucleoside
      derivatives of formula (I) (e.g. 6-iodouridine and 6-iodouridine
      monophosphate) in the treatment or prevention of viral infections
      (e.g. Flavivridae, Bunyaviridae, or Togaviridae, or viral
      infections of hepatitis C, hepatitis B, herpes, influenza, HIV,
      polio, Coxsackie A/B, rhino, small pox, Ebola, West Nile, or
      corona virus) and/or bacterial infections (e.g. H. pylori, S.
      Aureus, B. anthracis, Mycobacterial tuberculosis, M. leprae, M.
      avium, P. aueruginosa, Streptococcal species, and Pneumocystis
      carinii).<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Method for the production of an agent against an infectious
        disease</b><b><br>
      </b><b>US2010021556</b><b><br>
      </b><br>
      Also published as: DE102006052504 // ZA200903936 // CN101686999 //
      RU2009118361 // JP2010508367<br>
      <br>
      Disclosed is a method for producing an agent against an infectious
      disease, particularly HIV, Ebola, or similar. In said method, a
      pressurized, especially medical oxygen is swirled into a solution
      containing at least one plant component particularly in the form
      of an extract.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>METHOD OF ACCELERATED VACCINATION AGAINST EBOLA VIRUSES</b><b><br>
      </b><b>US8017130</b><b><br>
      </b><br>
      Also published as: WO2005012538 // US7635485 <br>
      <br>
      The present invention relates to genetic vaccines for stimulating
      cellular and humoral immune responses in humans and other hosts,
      and, in particular, relates to recombinant viruses that express
      heterologous antigens of pathogenic viruses, in single dose form.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>IMMUNOGENIC COMPOSITIONS AND VACCINES FOR EBOLA</b><b><br>
      </b><b>US7736656</b><b><br>
      </b><br>
      Using CTL epitopes to the Ebola GP, NP, VP24, VP30, VP35 and VP40
      virion proteins, a method and composition for use in inducing an
      immune response which is protective against infection with Ebola
      virus is described.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>D-GLUCOPYRANOSE 1-[3,5-BIS
        (1,1-DIMETHYLETHY)-4-HYDROXYBENZOATE] AND ITS DERIVATIVES,
        PREPARATION AND USE THEREOF</b><b><br>
      </b><b>US2010016244 </b><b><br>
      </b><br>
      Also published as: WO2008000920 // EP2041152 <br>
      <br>
      The invention relates to a D-glucopyranose
      1-[3,5-bis(1,1-dimethyl-ethyl)-4-hydroxybenzoate compound defined
      by formula (I). It applies in particular to the preparation and
      the use of this compound and of its derivatives for the
      preparation of medicaments for the treatment and/or prevention of
      infections with enveloped viruses, and in particular, in humans,
      the herpes virus, the Aids virus, the flu virus, the hepatitis B
      virus, the hepatitis C virus, the dengue virus and the ebola
      virus, and, in animals, the porcine pseudorabies virus, for
      example.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Sulfonyl Semicarbazides, Semicarbazides and Ureas,
        Pharmaceutical Compositions Thereof, and Methods for Treating
        Hemorrhagic Fever Viruses, Including Infections Associated with
        Arena Viruses</b><b><br>
      </b><b>US8642596</b><b><br>
      </b><br>
      Also published as: WO2006062898 // JP5285276<br>
      <br>
      Compounds, methods and pharmaceutical compositions for treating
      viral infections, by administering certain novel semicarbazides,
      sulfonyl carbazides, ureas and related compounds in
      therapeutically effective amounts are disclosed. Methods for
      preparing the compounds and methods of using the compounds and
      pharmaceutical compositions thereof are also disclosed. In
      particular, the treatment and prophylaxis of viral infections such
      as caused by hemorrhagic fever viruses is disclosed, i.e.,
      including but not limited to Arenaviridae (Junin, Machupo,
      Guanavito, Sabia and Lassa), Filoviridae (ebola and Marburg
      viruses), Flaviviridae (yellow fever, omsk hemorrhagic fever and
      Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley
      fever).<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A
        FILOVIRUS INFECTION</b><b><br>
      </b><b>US8168604</b><b><br>
      </b><br>
      Also published as: WO2006050414<br>
      <br>
      The invention provides antisense antiviral compounds and methods
      of their use and production in inhibition of growth of viruses of
      the Filoviridae family, and in the treatment of a viral infection.
      The compounds and methods relate to the treatment of viral
      infections in mammals including primates by Ebola and Marburg
      viruses. The antisense antiviral compounds are morpholino
      oligonucleotides having: a) a nuclease resistant backbone, b)
      15-40 nucleotide bases, and c) a targeting sequence of at least 15
      bases in length that hybridizes to a target region selected from
      the following: i) the Ebola virus AUG start site region of VP24;
      ii) the Ebola virus AUG start site region of VP35; iii) the
      Marburg virus AUG start site region of VP24; or iv) the Marburg
      virus AUG start site region of NP.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES</b><b><br>
      </b><b>US2009170803 </b><b><br>
      </b><br>
      Also published as: WO03086408 // JP2006515829 // EP1496911<br>
      <br>
      The present invention provides a therapeutic method for treating
      biological diseases that includes the administration of an
      effective amount of a suitable antibiotic agent, antifungal agent
      or antiviral agent in conjunction with an A2A adenosine receptor
      agonist. If no anti-pathogenic agent is known the A2A agonist can
      be used alone to reduce inflammation, as may occur during
      infection with antibiotic resistant bacteria, or certain viruses
      such as those that cause SARS or Ebola. Optionally, the method
      includes administration of a type IV PDE inhibitor.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Optimized vaccines to provide protection against Ebola and
        other viruses</b><b><br>
      </b><b>ZA200703260 </b><b><br>
      </b><br>
      <hr size="2" width="100%"><br>
      <b>New pharmaceutical composition, useful for preventing or
        treating viral or bacterial infections caused by a pathogen
        selected from HIV-1 virus, Ebola virus, hepatitis C virus,
        Mycobacterium tuberculosis and Helicobacter pylori</b><b><br>
      </b><b>AT505842 </b><b><br>
      </b><br>
      A pharmaceutical composition comprising polypeptide comprising any
      of fully defined 135 amino acids (SEQ ID NO1-3) given in the
      specification, is new. An independent claim is a complementary DNA
      (cDNA) encoding for polypeptide comprising any of SEQ ID NO. 1-3.
      - ACTIVITY : Virucide; Antibacterial; Anti-HIV; Antiinflammatory;
      Hepatotropic; Antitubercular; Tuberculostatic. <br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Assays for assembly of Ebola Virus Nucleocapsids</b><b><br>
      </b><b>ZA200501243 </b><b><br>
      </b><br>
      <hr size="2" width="100%"><br>
      <b>VIRAL TREATMENT</b><b><br>
      </b><b>WO2007100525 </b><b><br>
      </b><br>
      SARS, Ebola, Marburg, West Nile, German Measles, Yellow Fever,
      Saint Louis Encephalitis, Japanese Encephalitis, California
      Encephalitis, Human T-cell Leukemia, Newcastle Disease,
      respiratory tract infection and bronchitis, Lymphocytic
      Choriomeningitis, Lassa Hemorrhagic Fever, and Hanta Hemorrhagic
      Fever are treated by IM injection of a mixture comprising a first
      ingredient selected from the group consisting of procaine,
      chloroprocaine, tetracaine, chlorotetracaine, bromoprocaine,
      proparacaine, fluoroprocaine and benzocaine, and a second
      ingredient selected from the group consisting of dexamethasone,
      flumethasone and betamethasone.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>TREATMENT OF HEMORRHAGIC VIRAL INFECTIONS USING A TISSUE FACTOR
        INHIBITOR</b><b><br>
      </b><b>WO2007092607 </b><b><br>
      </b><br>
      The present invention relates to novel methods for the treatment
      of hemorrhagic viral infections, such as Ebola and Marburg virus,
      by administering a tissue factor inhibitor.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>SARS AND EBOLA INHIBITORS AND USE THEREOF, AND METHODS FOR
        THEIR DISCOVERY</b><b><br>
      </b><b>WO2008045017 </b><b><br>
      </b><br>
      The instant invention is drawn to methods useful for the treatment
      or the prevention of a viral infection. The methods include
      administering at least one compound that is an inhibitor of
      cathepsin L to an individual. The methods are particularly useful
      in individuals infected with, or at risk of infection with, SARS
      virus or Ebola virus. The invention also includes methods of
      identifying potential therapeutics for use in the methods of
      treatment or prevention of a viral infection.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>GENERATION OF VIRUS-LIKE PARTICLES AND USE AS PANFILOVIRUS
        VACCINE</b><b><br>
      </b><b>WO2006046963 </b><b><br>
      </b><br>
      In this application are described filoviruslike particles for both
      Ebola and Marburg and their use as a diagnostic and therapeutic
      agent as well as a filovirus vaccine. Also described are the
      association of Ebola and Marburg with lipid rafts during assembly
      and budding, and the requirement of functional rafts for entry of
      filoviruses into cells.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>PRODUCTION OF PEPTIDES IN PLANTS AS VIRAL COAT PROTEIN FUSION</b><b><br>
      </b><b>WO2005108564 </b><b><br>
      </b><br>
      Vaccines and diagnostic composition are made and used for
      preventing, treating and detecting antigens from a papilloma
      virus, ebola virus, HIV virus, Rift Valley Fever virus or a
      parvovirus. The epitopes of these viruses are produced as
      genetically engineered fusion peptides in plants by infection with
      a recombinant tobamovirus vectors to express fusion proteins
      containing the epitope peptides.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>IDENTIFICATION OF TWO LINEAR EPITOPES ON EBOLA OR MARBURG VIRUS
        GLYCOPROTEINS CRITICAL FOR INFECTION</b><b><br>
      </b><b>WO2005063798 </b><b><br>
      </b><br>
      The present invention relates to a linear domain encompassing F88
      and a linear domain encompassing F159 or functional equivalents
      thereof, substantially in isolation from sequences naturally
      occurring adjacent thereto in the Ebola or Marburg glycoprotein.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>EBOLA PEPTIDES AND IMMUNOGENIC COMPOSITIONS CONTAINING SAME</b><b><br>
      </b><b>US7267823</b><b><br>
      </b><b>WO2005023837 </b><b><br>
      </b><br>
      Also published as: WO2005023837 // EP1608393<br>
      <br>
      Using CTL epitopes to the Ebola GP, NP, VP24, VP30, VP35 and VP40
      virion proteins, a method and composition for use in inducing an
      immune response which is protective against infection with Ebola
      virus is described.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Immunization for ebola virus infection</b><b><br>
      </b><b>US6852324 </b><b><br>
      </b><br>
      Ebola virus vaccines comprising nucleic acid molecules encoding
      Ebola viral proteins are provided. In one embodiment, the nucleic
      acid molecule encodes the transmembrane form of the viral
      glycoprotein (GP). In another embodiment, the nucleic acid
      molecule encodes the secreted form of the viral glycoprotein
      (sGP). In yet another embodiment, the nucleic acid molecule
      encodes the viral nucleoprotein (NP). Methods for immunizing a
      subject against disease caused by infection with Ebola virus are
      also provided.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Targeting gene transfer vectors to certain cell types by
        pseudotyping with viral glycoprotein</b><b><br>
      </b><b>US2005130129 </b><b><br>
      </b><br>
      Also published as: WO9937331 // EP1056478 // EP1056478 //
      AU2560999 <br>
      <br>
      The present invention provides compositions and methods for
      targeting gene transfer vectors to certain cell types by
      pseudotyping with a transmembrane form of viral glycoprotein, such
      as that from Ebola virus. The methods comprise the step of
      administering to a cell population a gene to be transferred
      operatively linked to an appropriate transfer vehicle, wherein the
      transfer vehicle is associated with a transmembrane form of viral
      glycoprotein.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Compositions and methods for detecting, preventing, and
        treating African Hemorrhagic Fever</b><b><br>
      </b><b>US6713069 </b><b><br>
      </b><br>
      There is a substantial degree of structural similarity (although
      not sequence similarity) between the carboxy-terminal one-third of
      Filovirus glycoprotein and the transmembrane proteins of the very
      distantly related retroviruses, especially those of avian sarcoma
      viruses. The high degree of structural similarity implies
      functional homology as well. A number of compounds that are useful
      in the diagnosis and treatment of African hemorrhagic fever
      ("AHF") are disclosed. AHF infections (e.g., Ebola, Marburg) may
      be inhibited with low concentrations of peptides or antibodies of
      low toxicity. For example, analogs of a portion of the natural
      fusion glycoprotein of a Filovirus may be used to inhibit the
      normal fusion process of the virus in vivo, thus preventing or
      limiting infection.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Methods and compositions for use in the treatment of filovirus
        mediated disease conditions</b><b><br>
      </b><b>US7803555</b><b><br>
      </b><b>US6933108</b><b><br>
      </b><br>
      Methods and compositions are provided for at least slowing the
      progression of a filovirus mediated disease condition in a host.
      In the subject methods, an effective amount of an agent that at
      least reduces the amount of folate receptor mediated filovirus
      cell entry is administered to the host. The subject methods find
      use in both the prevention and treatment of filovirus associated
      disease conditions, including Marburg and Ebola-Zaire virus
      mediated disease conditions.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Ebola virion proteins expressed from venezuelan equine
        encephalitis (VEE) virus replicons</b><b><br>
      </b><b>US6984504</b><b><br>
      </b><br>
      Also published as: WO0000617 <br>
      <br>
      Using the Ebola GP, NP, VP24, VP30, VP35 and VP40 virion proteins,
      a method and composition for use in inducing an immune response
      which is protective against infection with Ebola virus is
      described.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Selenoproteins, coding sequences and methods</b><b><br>
      </b><b>US6303295 </b><b><br>
      </b><br>
      The present disclosure provides a method for the identification of
      nucleotide sequences which encode selenoproteins. Nucleotide
      sequences are translated in all potential reading frames, those
      with a relatively large number of UGA or TGA codons are noted, and
      frameshift-dependent open reading frames and SECIS elements are
      identified as associated with selenoprotein coding sequences,
      especially those within or overlapping known open reading frames.
      Further provided are selenoprotein coding sequences which are
      associated with certain viruses (e.g., HIV and Ebola),
      cancer-related genes and coding sequences related to normal
      functioning of the immune system.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Production of peptides in plants as viral coat protein fusions</b><b><br>
      </b><b>US2004170606 </b><b><br>
      </b><br>
      Vaccines and diagnostic composition are made and used for
      preventing, treating and detecting antigens from a papilloma
      virus, ebola virus, HIV virus, Rift Valley Fever virus or a
      parvovirus. The epitopes of these viruses are produced as
      genetically engineered fusion peptides in plants by infection with
      a recombinant tobamovirus vectors to express fusion proteins
      containing the epitope peptides.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Monoclonal antibodies to Ebola glycoprotein</b><b><br>
      </b><b>US6630144 </b><b><br>
      </b><br>
      Also published as: WO0116183 // WO0116183 // AU7089600<br>
      <br>
      In this application are described Ebola GP monoclonal antibodies
      and epitopes recognized by these monoclonal antibodies. Also
      provided are mixtures of antibodies of the present invention, as
      well as methods of using individual antibodies or mixtures thereof
      for the detection, prevention, and/or therapeutical treatment of
      Ebola virus infections in vitro and in vivo.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Adenovirus vector with multiple expression cassettes</b><b><br>
      </b><b>US6964762</b><b><br>
      </b><b>US6544780 </b><b><br>
      </b><br>
      Also published as: WO0191536 // ZA200209676<br>
      <br>
      Genetic vaccines and methods are provided for enhancing the
      immunity of a host such as a human to one or more pathogens. In
      one embodiment, a recombinant benign virus is provided as the
      genetic vaccine. The recombinant virus comprises: an antigen
      sequence heterologous to the recombinant virus that encodes a
      viral antigen from a pathogenic virus, expression of the viral
      antigen eliciting an immune response directed against the viral
      antigen and cells expressing the viral antigen in a host upon
      infection of the host by the recombinant virus; and an
      immuno-stimulator sequence heterologous to the recombinant virus
      that encodes an immuno-stimulator whose expression in the host
      enhances the immunogenicity of the viral antigen. The recombinant
      virus is replication-incompetent and does not causes a malignancy
      naturally associated with the pathogenic virus in the host. The
      genetic vaccines can be used for immunizing a host against a wide
      variety of pathogens, such as HIV, Ebola virus, hepatitis B virus,
      hepatitis C virus, influenza virus, pathogenic bacteria and
      parasites.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Pseudotyped retroviruses</b><b><br>
      </b><b>US7981656</b><b><br>
      </b><br>
      Also published as: WO03102219 // AU2003237374<br>
      <br>
      Pseudotyped retroviruses having viral glycoproteins with modified
      O glycosylation regions are provided. Also provided are methods
      for making the pseudotyped retroviruses of the present invention
      and for using the pseudotyped retroviruses for transduction of
      target cells. Cells for stably producing the pseudotyped
      retroviruses or the present invention are also provided.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Chimeric ebola virus envelopes and uses therefor</b><b><br>
      </b><b>US2005255123 </b><b><br>
      </b><br>
      Also published as: WO03092582 // AU2003232004<br>
      <br>
      Chimeric ebola envelope proteins and uses therefore are described.
      The chimeric envelope proteins are useful for packaging viral
      vectors and targeting these vectors in vivo, to lung cells
      following intratracheal delivery or for delivery of molecules, ex
      vivo, to macrophages and dendritic cells. In another aspect, also
      provided herein are immunogenic compositions which contain ebola
      envelope proteins and uses thereof.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Mobile air decontamination method and device</b><b><br>
      </b><b>US2004047776 </b><b><br>
      </b><br>
      Air decontamination method and device designed for bioterrorism,
      nerve gas, toxic mold, small pox, Ebola, anthrax and other agents
      require built in air sampling, rapid filter changes and the
      ability to use a mobile, transportable and connectable system in
      positive mode to push contaminates away or in negative mode to
      contain a toxin from spreading. This application combines features
      in respirators, industrial and hospital grade air filtration with
      the ability to provide air testing to guide the connection of the
      device with other treatment modules or existing HVAC and other
      equipment. With this new flexibility, ozone, UV, absorption,
      Thermal destruction, filters and liquid chemical neutralization
      can be manually or automatically adapted for emergency response to
      both daily airborne contamination and military grade terrorist
      threats of airborne contamination. The air decontamination units
      may be used to decontaminate the air after industrial and medical
      contaminations and terrorist biological, chemical and radiological
      attacks, for example. Mobile isolation units, and methods of
      decontaminating rooms, are disclosed, as well as Well as infection
      control and emergency response usage as an emergency clean air
      supply when connected to escape hoods, decon tents, or containment
      barriers to protect structures from homes to business from outside
      toxic agents. The unit can be powered by normal AC, 120 volts or
      240 or be adapted to battery or field power supply units.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Lethal toxin cytopathogenicity and novel approaches to anthrax
        treatment</b><b><br>
      </b><b>US2003224403 </b><b><br>
      </b><br>
      Inhibition of LeTx activity is provided as a treatment of anthrax
      infection. In particular, inhibition of the apoptotic effects of
      LeTx is provided as a targeted means of specifically treating
      anthrax infection. Treatments include inhibition of the Fas/FasL
      signaling pathway, inhibition of the effects of sFasL, inhibition
      of proteases of the caspase family and protection from loss of
      mitochondrial transmembrane potential in infected cells.
      Additionally, treatments targeting inhibition of apoptosis induced
      by LeTx activity include enhancement of the ERK (MAPK)-signaling
      pathway by agents including GM-CSF. The method of treating an
      infectious disease also comprises administering a combination of
      an antitoxin substance, which protects host cells from microbial
      toxin, and an antibiotic to an infected person. The anti-toxin
      substance includes different apoptosis inhibitors. Infection
      against which the treatment of the invention are effective include
      any disease leading to apoptosis of host cells such as, but not
      limited to, anthrax, plague, Ebola, or Marburg.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Generation of virus-like particles and demonstration of lipid
        rafts as sites of filovirus entry and budding</b><b><br>
      </b><b>US2004057967 </b><b><br>
      </b><br>
      Also published as: WO03039477 //&nbsp; EP1461424 <br>
      <br>
      In this application is described a method for the formation of
      filovirus-like particles for both Ebola and Marburg and their use
      as a diagnostic and therapeutic agent as well as a filovirus
      vaccine. Also described is the association of Ebola and Marburg
      with lipid rafts during assembly and budding, and the requirement
      of functional rafts for entry of filoviruses into cells.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Multivalent vaccination using recombinant adenovirus</b><b><br>
      </b><b>US2003219458 </b><b><br>
      </b><br>
      Also published as: US2002155127 // ZA200403434 // WO03038057<br>
      <br>
      Genetic vaccines and multivalent vaccination methods are provided
      for enhancing the immunity of a host such as a human to one or
      more pathogens. In one embodiment, a recombinant adenovirus is
      provided for eliciting immune response of a host to viral
      pathogens. The recombinant adenovirus comprises: a first antigen
      sequence that is heterologous to a native progenitor of the
      recombinant adenovirus and encodes a first viral antigen from a
      first pathogenic virus, expression of which is under the
      transcriptional control of a first promoter; and a second antigen
      sequence that is heterologous to a native progenitor of the
      recombinant adenovirus and encodes a second viral antigen from a
      second pathogenic virus, expression of which is under the
      transcriptional control of a second promoter. Expression of the
      first and second antigen sequences elicit an immune response
      directed against the first and second viral antigens upon
      infection of the host by the recombinant virus. The genetic
      vaccines can be used for immunizing a host against a wide variety
      of pathogens, such as HIV, Ebola virus, Marburg virus, hepatitis
      virus, influenza virus, respiratory syncytial virus, and human
      papilloma virus.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Recombinant lentiviral vectors pseudotyped in envelopes
        containing filovirus binding domains</b><b><br>
      </b><b>US2004033604 </b><b><br>
      </b><br>
      Recombinant transfer viruses, comprising an HIV minigene carrying
      a desired molecule, packaged in an envelope containing at least
      the binding domain of the ebola envelope protein, are described.
      Also described are methods of producing these transfer viruses and
      methods of using these viruses to deliver genes to selected target
      cells. These transfer viruses are particularly useful for delivery
      of molecules, in vivo, to lung cells following intracheal delivery
      or for delivery of molecules, ex vivo, to macrophages and
      dendritic cells.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Use of bivalent or polyvalent trisaccharides as
        fusion-inhibitors in all HIV types, subtypes, groups, strains,
        and circulating recombinant forms</b><b><br>
      </b><b>US2007093452 </b><b><br>
      </b><br>
      This invention relates to compositions containing bivalent or
      polyvalent trisaccharides, specifically but not exclusively,
      melezitose and raffinose, and to their use in the
      treatment/prevention/cure of HIV and AIDS. In particular, such
      compositions can be used to competitively inhibit formation of the
      viral fusion complex. This invention also relates to compositions
      containing bivalent or polyvalent trisaccharides, specifically but
      not exclusively, melezitose and raffinose, and to their use in
      other viral infections such as Influenza and Ebola, and
      furthermore to their use in the treatment of cancer. This
      invention also relates to the identification of a formerly
      unidentified "density" present in the Phe43 cavity of HIV. This
      invention hereby identifies said density as cholesterol.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Monoclonal antibodies and complementarity-determining regions
        binding to Ebola glycoprotein</b><b><br>
      </b><b>US7335356</b><b><br>
      </b><b>US6875433</b><b><br>
      </b><br>
      Also published as: WO2004018649<br>
      <br>
      In this application are described Ebola GP monoclonal antibodies,
      epitopes recognized by these monoclonal antibodies, and the
      sequences of the variable regions of some of these antibodies.
      Also provided are mixtures of antibodies of the present invention,
      as well as methods of using individual antibodies or mixtures
      thereof for the detection, prevention, and/or therapeutical
      treatment of Ebola virus infections in vitro and in vivo.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Generation of virus-like particles and use as panfilovirus
        vaccine</b><b><br>
      </b><b>US2006099225 </b><b><br>
      </b><br>
      In this application are described filovirus-like particles for
      both Ebola and Marburg and their use as a diagnostic and
      therapeutic agent as well as a filovirus vaccine. Also described
      is the association of Ebola and Marburg with lipid rafts during
      assembly and budding, and the requirement of functional rafts for
      entry of filoviruses into cells.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Generation of virus-like particles and use as panfilovirus
        vaccine</b><b><br>
      </b><b>US7682618</b><b><br>
      </b><b><br>
      </b>In this application are described filovirus-like particles for
      both Ebola and Marburg and their use as a diagnostic and
      therapeutic agent as well as a filovirus vaccine. Also described
      is the association of Ebola and Marburg with lipid rafts during
      assembly and budding, and the requirement of functional rafts for
      entry of filoviruses into cells.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>IMMUNIZATION FOR EBOLA VIRUS INFECTION</b><b><br>
      </b><b>WO9932147 </b><b><br>
      </b><br>
      Ebola virus vaccines comprising nucleic acid molecules encoding
      Ebola viral proteins are provided. In one embodiment, the nucleic
      acid molecule encodes the transmembrane form of the viral
      glycoprotein (GP). In another embodiment, the nucleic acid
      molecule encodes the secreted form of the viral glycoprotein
      (sGP). In yet another embodiment, the nucleic acid molecule
      encodes the viral nucleoprotein (NP). Methods for immunizing a
      subject against disease caused by infection with Ebola virus are
      also provided.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Assays for assembly of ebola virus nucleocapsids</b><b><br>
      </b><b>US7449190</b><b><br>
      </b><br>
      Also published as: WO2004007747 // JP2005533111 // EP1543165<br>
      <br>
      The present invention relates to assays for the identification of
      compounds that inhibit assembly of NP, VP35, and VP24, or inhibit
      the glycosylation of NP, required for nucleocapsid formation, for
      use as anti-viral agents. The invention also relates to assays for
      the identification of compounds that block glycosylation of
      proteins having a glycosylation domain that is substantially
      homologous to a glycosylation domain of NP required for
      polymerization. The invention further relates to pseudoparticles
      for presentation of antigens or antigenic epitopes for immunogenic
      or vaccination purposes.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>PRODUCTION OF PEPTIDES IN PLANTS AS VIRAL COAT PROTEIN FUSIONS</b><b><br>
      </b><b>WO2004032622 </b><b><br>
      </b><br>
      Also published as: EP1549140 // CA2497798<br>
      <br>
      Vaccines and diagnostic composition are made and used for
      preventing, treating and detecting antigens from a papilloma
      virus, ebola virus, HIV virus, Rift Valley Fever virus or a
      parvovirus. The epitopes of these viruses are produced as
      genetically engineered fusion peptides in plants by infection with
      a recombinant tobamovirus vectors to express fusion proteins
      containing the epitope peptides.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>RECOMBINANT LENTIVIRAL VECTORS PSEUDOTYPED IN ENVELOPES
        CONTAINING FILOVIRUS BINDING DOMAINS</b><b><br>
      </b><b>WO0183730</b><b><br>
      </b><br>
      Also published as: AU5372801<br>
      <br>
      Recombinant transfer viruses, comprising an HIV minigene carrying
      a desired molecule, packaged in an envelope containing at least
      the binding domain of the ebola envelope protein, are described.
      Also described are methods of producing these transfer viruses and
      methods of using these viruses to deliver genes to selected target
      cells. These transfer viruses are particularly useful for delivery
      of molecules, in vivo, to lung cells following intracheal delivery
      or for delivery of molecules, ex vivo, to macrophages and
      dendritic cells.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Method to reduce inflammatory response in transplanted tissue</b><b><br>
      </b><b>US7427606</b><b><br>
      </b><br>
      The present invention provides a therapeutic method for treating
      biological diseases that includes the administration of an
      effective amount of a suitable antibiotic agent, antifungal agent
      or antiviral agent in conjunction with an A2A adenosine receptor
      agonist. If no anti-pathogenic agent is known the A2A agonist can
      be used alone to reduce inflammation, as may occur during
      infection with antibiotic resistant bacteria, or certain viruses
      such as those that cause SARS or Ebola. Optionally, the method
      includes administration of a type IV PDE inhibitor.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>METHOD OF PREPARING HETEROLOGICAL IMMUNOGLOBULINS FOR VIRAL
        INFECTIONS MARBURG AND EBOLA CONTROL</b><b><br>
      </b><b>RU2089217 </b><b><br>
      </b><br>
      <hr size="2" width="100%"><br>
      <b>RECOMBINANT PLASMID DNA pCL1 ENCODING POLYPEPTIDE WITH PROPERTY
        OF HUMAN LIGHT CHAIN ANTIBODY AGAINST EBOLA VIRUS, RECOMBINANT
        PLASMID DNA pCH1 ENCODING POLYPEPTIDE WITH PROPERTY OF INDICATED
        ANTIBODY HEAVY CHAIN AND THEIR USING</b><b><br>
      </b><b>RU2285043 </b><b><br>
      </b><b><br>
      </b>FIELD: biotechnology, genetic engineering, virology, medicine.
      ^ SUBSTANCE: invention reports about the construction of
      recombinant plasmid DNAs pCL1 and pCH1 in vitro comprising
      artificial genes encoding light and heavy chains of human
      full-scale antigen against Ebola virus prepared by genetic
      engineering methods and created on basis of variable fragments of
      recombinant antibody 4d1 light and heavy chains from phage library
      of human single-chain antibody, and human constant genes IgG1,
      cytomegalovirus promoter and polyadenylation BGH site. The
      combining use of plasmid DNA pCL1 and pCH1 provides the
      biosynthesis of human recombinant full-size antibodies of class
      IgG1 interacting with Ebola virus.; Using recombinant full-size
      antibodies raised against Ebola virus can be used as a basis for
      the development of preparations used in diagnosis and treatment of
      dangerous diseases caused by this infectious agent. ^ EFFECT:
      valuable medicinal properties of plasmid. <br>
      <br>
      <hr size="2" width="100%"><br>
      <b>METHOD OF PROPHYLAXIS OF VIRAL AEROGENIC INFECTIONS</b><b><br>
      </b><b>RU2105565 </b><b><br>
      </b><br>
      FIELD: medicine, veterinary science, virology. SUBSTANCE: method
      involves intramuscular or intranasal administration of reaferon
      and/or ridostin, and/or polyribonate before or at period of
      possible infection. EFFECT: enhanced effectiveness of viral
      aerogenic infections prophylaxis.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>DEVELOPMENT OF PREVENTIVE VACCINE FOR FILOVIRUS INFECTION IN
        PRIMATES</b><b><br>
      </b><b>US7094598</b><b><br>
      </b><br>
      Also published as: JP4198148 // WO03028632<br>
      <br>
      PROBLEM TO BE SOLVED: To provide methods of eliciting an immune
      response against a filovirus such as Ebola virus and for
      preventing diseases caused by infection with the filovirus. ;
      SOLUTION: Disclosed is an expression vector comprising a specific
      base sequence encoding virion glycoproteins or a base sequence
      having at least 95 to 100% identity to the base sequence, wherein
      the expression vector comprises base sequences directing
      expression.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>MONOCLONAL ANTIBODY AGAINST RESTON EBOLA VIRUS AND METHOD FOR
        DETECTING RESTON EBOLA VIRUS USING THE SAME</b><b><br>
      </b><b>JP2004315394</b><b><br>
      </b><br>
      PROBLEM TO BE SOLVED: To obtain a monoclonal antibody specific to
      Reston Ebola virus and to provide a method for differentiating and
      diagnosing Reston Ebola virus using the antibody. ; SOLUTION: The
      monoclonal antibody is specific to Reston Ebola virus, especially
      the monoclonal antibody recognizes an epitope composed of a region
      of an amino acid sequence specific to the virus among
      nucleoproteins that Reston Ebola virus has. The monoclonal
      antibody recognizes an epitope composed of a region of four or
      more of amino acid residues of sequence DPDIGQSK of a specific
      region in amino acid sequences among nucleoproteins that Reston
      Ebola virus has. The method for differentiating and diagnosing
      Reston Ebola virus by the antigen-catching ELISA (enzymelinked
      immunosorbent assay) process comprises using the monoclonal
      antibody specific to Reston Ebola virus.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>MONOCLONAL ANTIBODY RECOGNIZING EBOLA VIRUS</b><b><br>
      </b><b>JP2002306164</b><b><br>
      </b><br>
      PROBLEM TO BE SOLVED: To provide a monoclonal antibody
      specifically recognizing an Ebola virus. SOLUTION: A monoclonal
      antibody or its fragment recognizing the nucleoprotein of an Ebola
      virus.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>TREATING INFECTIONS</b><b><br>
      </b><b>WO0187229 </b><b><br>
      </b><br>
      Also published as: AU2001258675<br>
      <br>
      Phenolic antioxidants in combination with a delivery vehicle which
      avoids releasing the phenolic antioxidants in the stomach of a
      subject are disclosed for use in the prophylaxis and therapy of
      infections, especially retroviral infections by the HIV and
      filoviral infections by the Ebola virus. These compounds can be
      administered in combination with proteolytic enzymes and/or
      antioxidants.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Phosphonate ester antiviral compounds</b><b><br>
      </b><b>EP1914237 </b><b><br>
      </b><br>
      The present invention relates to phosphonate ester compounds
      formed by the covalent linking of a phosphonate selected from (a)
      cidofovir or tenofovir; (b) an antiviral nucleoside phosphonate or
      an antiproliferative nucleoside phosphonate; and (c) a derivative
      of cytosine arabinoside, gemcitabine, 5-fluorodeoxyuridine
      riboside, 2-chlorodeoxyadenosine, fludarabine or
      1-beta-D-arabinofuranoxyl-guanine; to an alkylpropanediol. The
      compounds are used in the preparation of medicaments for treating
      a viral disease in a subject in need thereof, wherein said viral
      disease is selected from the human immunodeficiency virus,
      influenza, the herpes simplex virus, the human herpes virus, the
      cytomegalovirus, the hepatitis B and C virus, the Epstein-Barr
      virus, the varicella zoster virus, the orthopox virus, the ebola
      virus and the papilloma virus.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Identifying viruses that cause hemorrhagic fever, e.g. Ebola
        virus, useful for early and rapid diagnosis, comprises
        hybridization of nucleic acid with an array of probes</b><b><br>
      </b><b>DE10121214 </b><b><br>
      </b><br>
      Identifying (i) viruses (A) that cause hemorrhagic fever and (ii)
      pathogens (B) that, from the disease symptoms, may be confused
      with (A) comprising detecting hybridization with nucleic acid
      probes on an array, is new.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>TROJAN INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF</b><b><br>
      </b><b>WO03064453</b><b><br>
      </b><br>
      Also published as: DE10304202 // AU2003208275<br>
      <br>
      The invention relates to active inhibitors - trojan inhibitors
      (TI) - and the use thereof in the form of specifically shaped
      trojan proteasome-inhibitors (TPI) or trojan assembling-inhibitors
      (TAI), such as proteasome-and assembling-inhibitors which are,
      initially, inactive and are only activated in the target cell by
      means of a specific protease for the target cell. According to the
      invention, said inhibitor can be used in the treatment of viral
      infections, whereby a virus-specific protease is expressed,
      particularly in HIV-infections and AIDS-therapy, and optionally in
      the inhibition of the release, maturing and replication of filo
      viruses, and in the treatment and prevention of viral haemorrhagic
      fever (activated by Ebola or Marburg-viruses) and in the therapy
      of tumoral diseases, whereby the tumour cells are characterised by
      a specific protease.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>Prepn and application of natural bamboo vinegar disinfectant
        liquid</b><b><br>
      </b><b>CN1547908</b><b><br>
      </b><br>
      The present invention collects filtrate produced during baking
      bamboo charcoal and utilizes it as natural bamboo vinegar
      disinfectant liquid. The natural bamboo vinegar liquid is used as
      main material for preparing bamboo vinegar liquid containing Ag,
      Zn, Cu and other metal ions, and is compounded with proper amount
      of stabilizer to prepare spray or concentrated preparation. The
      disinfectant of the present invention can kill various viruses and
      pathogenetic bacteria and is non-toxic and non-excitant, and may
      be used widely in preventing dandy fever, Ebola virus, bird flu
      and other infectious diseases, household disinfection, and killing
      fungus.<br>
      <br>
      <hr size="2" width="100%"><br>
      <b>POLYOXOMETALLATE ANTIFILOVIRAL COMPOSITION</b><b><br>
      </b><b>WO9921569 </b><b><br>
      </b><br>
      A method of prophylactic or therapeutic inhibition of Ebola virus
      and other filoviruses in a human or non-human animal patient which
      comprises administering to the patient an effective amount of a
      heteropolytungstate selected from one of the following formulae:
      AnM1-4WqOr, AnYMXW11O39, An[(FeOA)4P2W18O68],
      An[Co(OH)3(H2O)6(HPO4)2(P3W27O102)], or AnP2W15O56. Where A = a
      cation, n = number of cations for electrical neutrality; Y = a
      ligand; X = B, P, Si, Ge, Zn, Co, Fe, Ga, Ti, Zr, V or Cu; M is
      selected from various metals or combinations thereof; q = 9-11,
      15-18, 22, 30 or 34, and r = 39, 40, 56, 62, 65, 68, 78, 102, 112
      or 122.<br>
      <br>
      <hr size="2" width="100%"></blockquote>
    <div align="center"><img alt="" src="0logo.gif" height="82"
        width="124"><br>
      <br>
    </div>
    <div style="text-align: center;"><b>Your Support Maintains this
        Service -- </b><b><br>
      </b> <b><br>
      </b> <b>BUY</b><b><br>
      </b> <b><br>
      </b> <big><b>The</b><b> Rex Research Civilization Kit </b></big><b><br>
      </b> <b><br>
      </b> <b>... It's Your Best Bet &amp; Investment in Sustainable
        Humanity on Earth ... </b><b><br>
      </b><b> Ensure &amp; Enhance Your Survival &amp; Genome
        Transmission ...</b><b> </b><b><br>
      </b> <b>Everything @ rexresearch.com on a Data DVD ! </b><b><br>
      </b> <b><br>
      </b> <b><a href="order.htm"
          ">ORDER PAGE</a></b><b><br>
      </b> <b></b><b><br>
      </b><b> </b> </div>
    <hr style="width: 62%; height: 2px;">
    <script type="text/javascript">
var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
</script>
    <script type="text/javascript">
try{
var pageTracker = _gat._getTracker("UA-xxxxxx-x");
pageTracker._trackPageview();
} catch(err) {}
</script>
    <script type="text/javascript">
var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
</script>
    <script type="text/javascript">
try{
var pageTracker = _gat._getTracker("UA-xxxxxx-x");
pageTracker._trackPageview();
} catch(err) {}
</script>
  </body>
</html>
